Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Currax acquires Nalpropion, gaining weight-loss medicine Contrave

Executive Summary

Currax Pharmaceuticals LLC acquired 2018 start-up Nalpropion Pharmaceuticals Inc.. gaining worldwide rights to Nalpropion's sole product, the FDA-approved Contrave (bupropion/naltrexone; sold in the EU as Mysimba) weight-loss medication.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition

Related Companies